Interferon-Free Regimens in Development for HCV Genotypes 2, 3, & 4
Regimen Status/Sponsor Population Duration
ABT-267 + ABT-450/r +/− RBV Phase IIAbbVie Treatment-naive;HCV genotypes 2 & 3 Not Specified
FDC: ABT-267/ABT-450/r + ABT-333 + RBV Phase IIAbbVie Treatment-naive and treatment-experienced (no prior DAA) 12 weeks
asunaprevir + daclatasvir + BMS-791325 Phase II BMS Treatment-naive;HCV genotype 4 12 or 24 weeks
daclatasvir + sofosbuvir+/− RBV Phase IIBMS/Pharmasset Treatment-naive;non-cirrhotic;HCV genotypes 2 & 3
24 weeks
sofosbuvir + GS-5816 Phase II Gilead Treatment-naive, non-cirrhotic; HCV genotypes 2, 3, 4, 5, & 6 12 weeks
FDC: sofosbuvir/ledipasvir or sofosbuvir + GS-9669 Phase II Gilead Treatment-naive or null responders (no prior DAA); HCV genotype 4 12 weeks
FDC: sofosbuvir/ledipasvir +/− RBV Phase II GileadTreatment-naive; HCV genotype 3 12 weeks
sofosbuvir + RBV Phase II Gilead Interferon-ineligible or-intolerant; HCV genotypes 2 & 3 12 weeks
sofosbuvir + RBV Phase II Gilead All genotypes; no prior treatment with HCV nucleoside/tide; portal hypertension with or without hepatic decompensation 48 weeks Posttransplant 24 weeks Pretransplant (for hepatocellular carcinoma) 24 weeks
sofosbuvir + RBV Phase II Gilead Treatment-naive and treatment-experienced Egyptian adults; HCV genotype 4 12 or 24 weeks
sofosbuvir + RBV Phase III Gilead Prior sofosbuvir study participants; HCV genotypes 2 & 3 12 weeks Treatment-naive; interferon- intolerant, -ineligible, or -unwilling 12 weeks Treatment-experienced (no prior DAA); HCV genotypes 2 & 3 12 or 16 weeks